

MIFID II - Research
Have you arranged access?
[Click here to contact us](#)

DNB MARKETS

NORDIC NANOVECTOR

Datapoint set to debut at ASH 2018

Nordic Nanovector reported a slightly larger operating loss for Q4 than we had expected, but it has been spending heavily on clinical development, which we appreciate. Management guided imminent first patient treatment in the PARADIGME trial, and we still believe it is on track to get the trial data readout and first filing by the end of 2019. We keep our BUY recommendation but have trimmed our target price to NOK135 (NOK145) on the back of revised forecasts.

Slightly higher operating loss in Q4 than expected. The company is in a period of high spending on the clinical development programme; hence we do not see the higher than expected loss as a concern. The Q4 operating loss was cNOK102m, compared to our estimate of a loss of cNOK71m; the deviation was due entirely to higher development costs, while other costs were in line with our estimates.


Development timeline for PARADIGME should hold – but the risk has increased. The company previously announced in December that the first patient treated was imminent, i.e. in Q4 2017. However, it still has yet to happen, and management said at the Q4 presentation that it would issue a press release when the first patient had been dosed. We estimate the company needs to include all c130 patients in the PARADIGME trial before May/June 2019 to meet the data readout and filing commitment, which looks doable to us, but Nordic Nanovector cannot afford any major delays in the recruitment process.

Next major clinical data-point could be ASH 2018. We believe Nordic Nanovector will not report any additional clinical data until ASH 2018 in December, for maximum impact. We expect it to release the final results from the LYMRIT 37-01 trial at the conference (with focus on CR, ORR and DoR), as well as the first clinical data from the DLBCL trial.

We reiterate our BUY recommendation but have trimmed our target price to NOK135 (145) to reflect our forecast changes, primarily for higher clinical development costs.

BUY
TP: NOK135

NANO versus OSEBX (12m)



SUMMARY

Recommendation (prev.)	BUY (BUY)
Share price (NOK)	69.5
Target price (previous) (NOK)	135 (145)
Upside/downside potential (%)	94
Tickers	NANO NO, NANO.OL

CAPITAL STRUCTURE

No. of shares (m)	48.8
No. of shares fully dil. (m)	48.8
Market cap. (NOKm)	3,390
NIBD adj end-2018e (NOKm)	-406
Enterprise value adj (NOKm)	2,985
Net debt/EBITDA adj (x)	1.19

SHARE PRICE PERFORMANCE

Abs. 1/3/12m (%)	-14/-13/-36
Rel. 1/3/12m (%)	-13/-16/-55
High/Low 12m (NOK)	109/69
Free float (%)	63

Source: Company, DNB Markets (estimates)

NEXT EVENT

Q1 2018 report	30/05/2018
----------------	------------

ESTIMATE CHANGES (NOK)

Year-end Dec	2018e	2019e	2020e
EPS (old)	-5.99	-6.46	
EPS (new)	-6.99	-7.46	-5.72
Change (%)	nm	nm	nm
Sales (old)		0.60	
Sales (new)	0.50	0.60	35.27
Change (%)	nm	0.0	nm

Source: DNB Markets, Bloomberg

Year-end Dec	2014	2015	2016	2017	2018e	2019e	2020e
Revenue (NOKm)	0	0	0	0	1	1	35
EBITDA adj (NOKm)	-68	-182	-215	-315	-341	-363	-275
EBIT adj (NOKm)	-69	-183	-216	-317	-343	-366	-280
PTP (NOKm)	-64	-173	-235	-293	-341	-364	-279
EPS rep (NOK)	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
EPS adj (NOK)	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
DPS (NOK)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Revenue growth (%)	43.6	-0.6	-28.1	-3.8	65.6	20.0	5778.9
EV/Sales adj (x)	nm	nm	nm	nm	nm	nm	89.00
P/Book (x)	1.52	0.79	4.75	5.81	10.02	7.14	17.32
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company (historical figures), DNB Markets (estimates)


ANALYSTS

Patrik Ling
patrik.ling@dnb.se
+46 8 473 48 43

Please see the last two pages for important information. This research report was not produced in the US. Analysts employed by non-US affiliates are not registered/qualified research analysts with FINRA in the United States.

Investment case overview

Share price performance, DNB Markets' target price, bear- and bull-case scenarios



Source: FactSet, DNB Markets

Downside risks to our investment case

- We still expect Betalutin to have a meaningful clinical effect. The biggest risk we see is that the development programme (which we believe is ambitious) might incur further delays.
- There is much focus on the NHL market from many big pharmaceutical companies; hence the competitive environment might get tougher.
- Longer than expected approval times and changes to regulatory conditions.
- Lower realised prices than we factor into our model.

Source: DNB Markets

DNB Markets investment case and how we differ from consensus

- In our base case, the company will develop Betalutin all the way to the market and launch the product alone.
- The first indication should reach the market in H1 2020. We have applied a 50% probability adjustment to FL sales, but development costs are unadjusted.
- We estimate a global average price per patient of USD150,000 for Betalutin for all indications.

Source: DNB Markets

Target price methodology

- Our target price continues to be based mainly on a SOTP, which includes the period until the patent expires, and is probability-adjusted. We discount the values back to a NPV with a WACC of 10%.
- Our bull-case fair value is based on our SOTP valuation but with a higher peak penetration assumption than in our base case.
- Our bear-case fair value is based on our SOTP valuation but with a lower peak penetration assumption than in our base case.


Source: DNB Markets

Upside risks to our investment case

- The company could well become a target for consolidation in the industry.
- It might realise higher prices for Betalutin than we have factored in.
- With strong clinical data, the approval process might be speedier than we estimated and thus a launch might take place earlier than expected.

Source: DNB Markets

EBIT bridge 2017–2019e (NOKm)



Source: DNB Markets (forecasts), company (historical data)

Q4 review

Spending on clinical development pushes costs above expectations

Costs were somewhat higher than we had expected in Q4. The main deviation was explained by 'Other external costs', which primarily relate to the ongoing clinical trials and the start-up of future trials. From this perspective we believe Nordic Nanovector is spending money where it matters for shareholders, and do not see the higher spend as a concern. Payroll and personnel expenses were more or less in line with our estimates.

Q4 key highlights

(NOKm, except per share data)	Q4 2017			Deviation (%)		Deviation (Abs)		Q4 2016
	Actual	DNB	Cons.	DNB	Cons.	DNB	Cons.	Actual
Sales	0	0	n.a.	n.m.	n.m.	0	n.m.	0
EBIT reported	-102	-71	n.a.	-43%	n.m.	-31	n.m.	-65
EBIT margin (%)	n.m.	n.m.	n.m.					n.m.
Net financial items	16	-2	n.a.	1142%	n.m.	18	n.m.	6
Pre-tax profit	-86	-73	n.a.	-18%	n.m.	-13	n.m.	-59
EPS	-1.75	-1.5	n.a.	-17%	n.a.	n.a.	n.m.	-1.22
Growth YOY								
Group sales	-38%	213%	n.m.			-250%	n.m.	
EBITA Adj.	-56%	-9%	n.m.			-47%	n.m.	
EPS	-43%	-23%	n.m.			-20%	n.m.	
Cash position	757	735	n.a.	3%	n.m.	22	n.m.	1,018

Source: Company data (historical figures), DNB Markets (estimates).

Nordic Nanovector had cNOK757m cash at end-Q4, slightly higher than we had forecast. We believe this will be sufficient to finance the company until first approval for Betalutin in 3L FL. However, we calculate it will not be enough to fully commercialise the product; hence we have included a cNOK500m capital raising in late 2019 to fund the Betalutin launch.

Betalutin development plan

Management said the first patient in the PARADIGME trial will be dosed in H1 2018 (we believe this could mean any day – as the company only guides on half years). However, it has been somewhat optimistic in its previous communications, saying in Q4 2017 that it expected the first patient to be dosed last year. With some c30-40 sites planned for the trial (all those from the LYMRIT 37-01 trial plus some additional sites), we believe recruitment could be relatively quick, once the local paperwork is done and patients are starting to be admitted to the trial. In the event, we believe the company could have enough time to reach data readout from the trial in H2 2019.

Management is guiding for data readout and first filing in H2 2019. Assuming it files for approval in December 2019 and needs 3–4 months from the last patient visit to clean and lock the database and analyse the data, the last patient visit needs to take place around August 2019, on our calculations. Given the 3-month follow-up time from treatment to the first efficacy readout, the company needs to recruit the last patient some time before summer 2019, or about 15 months from now to recruit all c130 patients to the trial.

We believe this should be doable, on our assumption of c30–40 trial sites ultimately. While competition for patients in the 3L FL market has increased over the past couple of years, we believe that as Nordic Nanovector has presented strong data from the LYMRIT 37-01 trial, it should be reasonably easy to recruit patients when the trial fully kicks-off.

Next clinical data point – ASH 2018 most likely

We do not expect Nordic Nanovector to present any additional clinical data from completed and ongoing trials until ASH 2018. The data presented at ASH 2017 was strong in our view, but the factor that looked weaker than in the past was the Duration of Response (DoR); this was mainly due to a lot of new patients being included in the trial and as a result had a relatively short follow-up time. With LYMRIT 37-01 closed to additional patient recruits, we believe the company

28 February 2018

will want to wait until ASH 2018 before presenting new data in order to show a marked improvement in DoR compared with the last presentation.

Management has also guided the preliminary data readout from the phase I DLBCL trial during H2 2018. We believe it is aiming for ASH 2018 in December.

Summary and recommendation

We believe Nordic Nanovector can still meet its target of a Betalutin first filing in H2 2019. Management has said it will issue a press release once the first patient in the PARADIGME pivotal phase II trial has been dosed; we expect this press release to come soon. While we keep our BUY recommendation, we have trimmed our target price from NOK145 to NOK135 based on changes to our forecasts.

Forecast changes – P&L

(NOKm)	2018e	New 2019e	2020e	2018e	Old 2019e	2020e	2018e	Change 2019e	2020e
Revenues	1	1	35		1			0	
Cost of sales	0	0	-3		0			0	
Gross profit	1	1	32		1			0	
Operating expenses	-342	-363	-307	-293	-315		-49	-49	
EBITDA	-341	-363	-275	-292	-314		-49	-49	
EBITDA adj	-341	-363	-275	-292	-314		-49	-49	
EBITDA margin (%)	nm	nm	nm	nm	-52354.9	nm	nm	nm	nm
Depreciation	-2	-3	-5		-3			0	
EBITA	-343	-366	-280	-294	-317		-49	-49	
EBIT	-343	-366	-280	-294	-317		-49	-49	
EBIT adj	-343	-366	-280	-294	-317		-49	-49	
Net interest	2	2	1		2			0	
Net financial items	2	2	1		2			0	
PBT	-341	-364	-279	-292	-315		-49	-49	
Taxes	0	0	0		0			0	
Net profit	-341	-364	-279	-292	-315		-49	-49	
Adjustments to net profit	0	0	0	0	0		0	0	
Net profit adj	-341	-364	-279	-292	-315		-49	-49	
<i>Per share data (NOK)</i>									
EPS	-6.99	-7.46	-5.72	-5.99	-6.46		-1.00	-1.00	
EPS adj	-6.99	-7.46	-5.72	-5.99	-6.46		-1.00	-1.00	
DPS ordinary	0.00	0.00	0.00		0.00			0.00	
DPS extraordinary	0.00	0.00	0.00		0.00			0.00	
DPS	0.00	0.00	0.00		0.00			0.00	
<i>Other key metrics (%)</i>									
Revenue growth	65.6	20.0	5778.9	nm	nm	nm	nm	nm	nm
EBIT adj growth	nm	nm	nm	2.8	7.8	nm	nm	nm	nm
EPS adj growth	nm	nm	nm	4.1	7.9	nm	nm	nm	nm
Avg. number of shares (m)	51	51	51	51	51		0	0	
Capex	-8	-10	-10		-10			0	
OpFCF	-349	-373	-285	-300	-324		-49	-49	
Working capital	-78	-78	-78	-30	-30		-48	-48	
NIBD adj	-406	-535	-251	-435	-613		29	78	

Source: DNB Markets

Quarterly numbers

(NOKm)	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018e	Q2 2018e	Q3 2018e	Q4 2018e	Q1 2019e
Revenues	0	0	0	0	0	0	0	0	0	0	0
Cost of sales	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0
Operating expenses	-50	-65	-65	-76	-72	-101	-85	-85	-85	-85	-91
EBITDA	-50	-65	-65	-76	-72	-101	-85	-85	-85	-85	-91
Depreciation	0	0	0	0	0	-1	-1	-1	-1	-1	-1
EBITA	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
EBIT	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
Net interest	-11	6	10	10	-13	16	1	1	1	1	1
Net financial items	-11	6	10	10	-13	16	1	1	1	1	1
PBT	-61	-59	-56	-66	-86	-86	-85	-85	-85	-85	-91
Taxes	0	0	0	0	0	0	0	0	0	0	0
Net profit	-61	-59	-56	-66	-86	-86	-85	-85	-85	-85	-91
Adjustments to net profit	0	0	0	0	0	0	0	0	0	0	0
Net profit adj	-61	-59	-56	-66	-86	-86	-85	-85	-85	-85	-91

Per share data (NOK)

Growth and margins (%)

Revenues, QOQ growth	-1.3	1.3	-1.3	-15.4	63.6	-53.7	150.0	0.0	0.0	0.0	20.0
Revenues, YOY growth	2.6	-45.9	0.0	-16.5	38.5	-36.7	60.3	89.4	15.7	150.0	20.0
EPS adj, YOY growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Gross margin	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
EBITDA adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Depreciation/revenues	-383.3	-416.5	-357.7	-454.5	-334.3	-1086.0	-400.0	-400.0	-400.0	-400.0	-500.0
EBIT adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Adjustments to quarterly numbers

(NOKm)	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018e	Q2 2018e	Q3 2018e	Q4 2018e	Q1 2019e
EBITDA	-50	-65	-65	-76	-72	-101	-85	-85	-85	-85	-91
EBITDA adj	-50	-65	-65	-76	-72	-101	-85	-85	-85	-85	-91
EBITA	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
EBITA adj	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
EBIT	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
EBIT adj	-50	-65	-66	-76	-73	-102	-86	-86	-86	-86	-91
Net profit	-61	-59	-56	-66	-86	-86	-85	-85	-85	-85	-91
Net profit adj	-61	-59	-56	-66	-86	-86	-85	-85	-85	-85	-91

Source: Company (historical figures), DNB Markets (estimates)

Annual P&L

(NOKm)	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
Revenues	0	0	0	0	0	0	0	1	1	35
Cost of sales	0	0	0	0	0	0	0	0	0	-3
Gross profit	0	0	0	0	0	0	0	1	1	32
Operating expenses	-7	-13	-18	-69	-183	-216	-315	-342	-363	-307
EBITDA	-7	-13	-18	-68	-182	-215	-315	-341	-363	-275
Depreciation	-1	-1	0	0	-1	-1	-1	-2	-3	-5
EBITA	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
EBIT	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
Net interest	0	0	1	5	10	-19	23	2	2	1
Net financial items	0	0	1	5	10	-19	23	2	2	1
PBT	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
Taxes	0	0	0	0	0	0	0	0	0	0
Effective tax rate (%)	0	0	0	0	0	0	0	0	0	0
Net profit	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
Adjustments to net profit	0	0	0	0	0	0	0	0	0	0
Net profit adj	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
Avg. number of shares	0	6	9	20	42	49	51	51	51	51
<i>Per share data (NOK)</i>										
EPS	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
EPS adj	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
DPS ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<i>Growth and margins (%)</i>										
Revenue growth	nm	135.1	106.6	43.6	-0.6	-28.1	-3.8	65.6	20.0	5778.9
EPS adj growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Gross margin	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	90.3
EBITDA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBITDA adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Depreciation/revenues	-898.9	-526.2	-77.4	-78.6	-227.5	-369.4	-491.1	-400.0	-500.0	-14.2
EBIT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
PBT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Adjustments to annual P&L

(NOKm)	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
EBITDA	-7	-13	-18	-68	-182	-215	-315	-341	-363	-275
EBITDA adj	-7	-13	-18	-68	-182	-215	-315	-341	-363	-275
EBITA	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
EBITA adj	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
EBIT	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
EBIT adj	-7	-14	-18	-69	-183	-216	-317	-343	-366	-280
Net profit	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
Net profit adj	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
<i>Per share data (NOK)</i>										
EPS	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
Recommended adjustment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS adj	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72

Source: Company (historical figures), DNB Markets (estimates)

Cash flow

(NOKm)	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
Net profit	-7	-13	-17	-64	-173	-235	-293	-341	-364	-279
Change in net working capital	0	0	0	0	0	0	0	0	0	0
Cash flow from operations (CFO)	-6	-13	-17	-63	-172	-234	-292	-339	-361	-274
Capital expenditure	-1	0	0	3	-2	-1	-3	-8	-10	-10
Acquisitions/Investments	0	0	0	0	0	0	0	0	0	0
Cash flow from investing (CFI)	-1	0	0	3	-2	-1	-3	-8	-10	-10
Free cash flow (FCF)	-7	-13	-17	-61	-174	-236	-294	-347	-371	-284
Net change in debt	0	0	0	0	0	0	0	0	0	0
Other	-2	2	3	5	34	45	65	-4	0	0
Cash flow from financing (CFF)	12	2	90	318	580	510	33	-4	500	0
Total cash flow (CFO+CFI+CFF)	4	-11	73	257	406	275	-262	-351	129	-284
<i>FCFF calculation</i>										
Free cash flow	-7	-13	-17	-61	-174	-236	-294	-347	-371	-284
Less: net interest	0	0	-1	-5	-10	19	-23	-2	-2	-1
Less: acquisitions	0	0	0	0	0	0	0	0	0	0
Growth (%)										
CFO	-293.1	-102.7	-32.4	-277.3	-171.3	-36.3	-24.8	-16.1	-6.4	24.1
CFI	nm	108.7	-479.6	1031.8	-180.7	32.8	-67.8	-218.3	-25.0	0.0
FCF	-349.7	-76.1	-35.6	-254.5	-187.3	-35.4	-25.0	-17.9	-6.8	23.4
CFF	-13.9	-84.0	4759.6	253.4	82.5	-12.0	-93.6	-111.0	13916.0	-100.0
FCFF	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

28 February 2018

Balance sheet

(NOKm)	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
Assets	22	11	86	346	760	1,045	780	436	572	293
Inventories	0	0	0	0	0	0	0	0	0	0
Trade receivables	4	4	6	7	14	23	20	20	20	20
Other receivables	0	0	0	0	0	0	0	0	0	0
Current financial assets	0	0	0	0	0	0	0	0	0	0
Cash and cash equivalents	17	7	80	337	743	1,018	757	406	535	251
Current assets	21	11	86	344	758	1,042	776	426	555	271
Property, plant and equipment	1	0	0	2	3	3	4	10	17	22
Goodwill	0	0	0	0	0	0	0	0	0	0
Other intangible assets	0	0	0	0	0	0	0	0	0	0
Defferred tax assets	0	0	0	0	0	0	0	0	0	0
Non-current financial assets	0	0	0	0	0	0	0	0	0	0
Non-current assets	1	0	0	2	3	3	4	10	17	22
Total assets	22	11	86	346	760	1,045	780	436	572	293
Equity and liabilities	22	11	86	346	760	1,045	780	436	572	293
Total equity to the parent	20	8	79	330	713	949	680	339	475	196
Total equity	20	8	79	330	713	949	680	339	475	196
Trade payables	1	2	4	6	20	53	29	29	29	29
Other payables and accruals	1	1	3	9	27	42	68	68	68	68
Short-term debt	0	0	0	0	0	0	0	0	0	0
Total current liabilities	1	3	7	16	48	95	97	97	97	97
Long-term debt	0	0	0	0	0	0	0	0	0	0
Pension liabilities	0	0	0	0	0	0	0	0	0	0
Other non-current liabilities	0	0	0	0	0	0	4	0	0	0
Total non-current liabilities	0	0	0	0	0	0	4	0	0	0
Total liabilities	1	3	7	16	48	95	101	97	97	97
Total equity and liabilities	22	11	86	346	760	1,045	780	436	572	293
<i>Key metrics</i>										
Net interest bearing debt	-17	-7	-80	-337	-743	-1,018	-757	-406	-535	-251

Source: Company (historical figures), DNB Markets (estimates)

Valuation ratios

(NOKm)	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
<i>Enterprise value</i>										
Share price (NOK)				28.00	14.10	96.75	81.00	69.50	69.50	69.50
Number of shares (m)	0.32	6.37	8.84	26.55	44.52	48.78	48.78	48.78	48.78	48.78
Market capitalisation				743	628	4,720	3,952	3,390	3,390	3,390
Net interest bearing debt	-17	-7	-80	-337	-743	-1,018	-757	-406	-535	-251
Adjustments to NIBD	0	0	0	0	0	0	0	0	0	0
Net interest bearing debt adj	-17	-7	-80	-337	-743	-1,018	-757	-406	-535	-251
EV				406	-116	3,702	3,195	2,985	2,855	3,139
EV adj				406	-116	3,702	3,195	2,985	2,855	3,139
<i>Valuation</i>										
EPS	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
EPS adj	-21.42	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.99	-7.46	-5.72
DPS ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
P/E				-7.9	-3.3	-19.2	-13.4	-9.9	-9.3	-12.2
P/E adj				-7.9	-3.3	-19.2	-13.4	-9.9	-9.3	-12.2
P/B				1.52	0.79	4.75	5.81	10.02	7.14	17.32
Average ROE	-40.7%	-95.5%	-39.3%	-31.1%	-33.1%	-28.3%	-36.0%	-67.0%	-89.5%	-83.2%
Dividend yield				0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/SALES				924.74	-264.64	11788.65	10579.25	5969.24	4759.10	89.00
EV/SALES adj				924.74	-264.64	11788.65	10579.25	5969.24	4759.10	89.00
EV/EBITDA				-5.9	0.6	-17.2	-10.1	-8.8	-7.9	-11.4
EV/EBITDA adj				-5.9	0.6	-17.2	-10.1	-8.8	-7.9	-11.4
EV/EBIT				-5.9	0.6	-17.1	-10.1	-8.7	-7.8	-11.2
EV/EBIT adj				-5.9	0.6	-17.1	-10.1	-8.7	-7.8	-11.2
EV/NOPLAT				-5.9	0.6	-17.1	-10.1	-8.7	-7.8	-11.2
EV/OpFCF (taxed)				-6.2	0.6	-17.1	-10.1	-8.5	-7.7	-11.0

Source: Company (historical figures), DNB Markets (estimates)

Key accounting ratios

	2011	2012	2013	2014	2015	2016	2017	2018e	2019e	2020e
<i>Profitability (%)</i>										
ROA	-37.4	-81.7	-35.1	-29.5	-31.2	-26.1	-32.2	-56.1	-72.2	-64.5
<i>Return on invested capital (%)</i>										
Net PPE/revenues	1456.3	186.6	109.8	357.9	642.3	1001.6	1382.1	2034.8	2862.3	62.9
Working capital/revenues	3425.1	498.8	-380.5	-1917.2	-7651.3	-22953.2	-25666.2	-15502.4	-12918.7	-219.7
<i>Cash flow ratios (%)</i>										
FCF/revenues	-11350.2	-8500.0	-5577.5	-13772.2	-39796.6	-75002.9	-97504.3	-69416.5	-61806.6	-805.0
FCF/market capitalisation				-8.1	-27.7	-5.0	-7.5	-10.2	-10.9	-8.4
CFO/revenues	-9921.9	-8552.6	-5480.7	-14400.5	-39286.7	-74525.8	-96672.2	-67816.5	-60139.9	-776.7
CFO/market capitalisation				-8.5	-27.4	-5.0	-7.4	-10.0	-10.6	-8.1
CFO/capex	-694.7	16235.5	-5661.6	2292.3	-7705.7	-15621.6	-11617.6	-4238.5	-3608.4	-2739.6
CFO/current liabilities	-432.0	-385.1	-231.8	-408.2	-360.5	-245.2	-300.2	-348.7	-371.1	-281.7
Cash conversion ratio	104.9	93.6	100.3	95.1	100.7	100.1	100.4	101.8	101.9	101.8
Capex/revenues	1428.3	-52.7	96.8	-628.2	509.8	477.1	832.1	1600.0	1666.7	28.3
Capex/depreciation	158.9	-10.0	125.1	-799.3	224.1	129.1	169.5	400.0	333.3	200.0
OpFCF margin	-11771.7	-8699.5	-5936.9	-14919.3	-42180.5	-69012.7	-105149.7	-69816.5	-62139.9	-807.9
Total payout ratio	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>Leverage and solvency (x)</i>										
Interest cover	-3048.33	-32252.69	-158.41	-28816.44	-95.15	-7.09	nm	nm	nm	nm
EBIT/interest payable	-3168.13	-32962.60	-169.72	-31100.36	-101.95	-7.45				
EBITA adj/interest payable	-3168.13	-32962.60	-169.72	-31100.36	-101.95	-7.45				
Cash coverage	24.54	43.86	16.25	13.55	17.48	-11.44	13.64	170.54	181.42	274.96
Net debt/EBITDA	2.67	0.51	4.45	4.93	4.08	4.73	2.40	1.19	1.47	0.91
Total debt/total capital (BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
LTD / (LTD + equity (MV))				0.00	0.00	0.00	0.00	0.00	0.00	0.00
<i>Cash conversion cycle</i>										
Inventory turnover days										0.0
Receivables turnover days	20883.9	9927.3	7242.4	5877.1	11854.6	27173.9	23841.0	14400.0	12000.0	204.1
Credit period	nm	nm	nm	nm	nm	nm	nm	nm	nm	3122.1
Cash conversion cycle										-2918.0

Source: Company (historical figures), DNB Markets (estimates)

Important Information

Company: Nordic Nanovector
 Coverage by Analyst: Patrik Ling
 Date: 28/02/2018

This report has been prepared by DNB Markets, a division of DNB Bank ASA. DNB Bank ASA is a part of the DNB Group. This report is based on information obtained from public sources that DNB Markets believes to be reliable but which DNB Markets has not independently verified, and DNB Markets makes no guarantee, representation or warranty as to its accuracy or completeness. This report does not, and does not attempt to, contain everything material which there is to be said about the Company. Any opinions expressed herein reflect DNB Markets' judgement at the time the report was prepared and are subject to change without notice. The report is planned updated minimum every quarter.

Any use of non-DNB logos in this report is solely for the purpose of assisting in identifying the relevant issuer. DNB is not affiliated with any such issuer.

This Report is for clients only, and not for publication, and has been prepared for information purposes only by DNB Markets, a division of DNB Bank ASA.

This research report is the property of DNB Markets. DNB Markets retains all intellectual property rights (including, but not limited to, copyright) relating to the research report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of the research report contents, either partially or in full, without DNB Markets' explicit and prior written consent. However, buy-side investment firms may use the research when making investment decisions, and may also base investment advice given to clients on the research. Such use is dependent on the buy-side investment firm citing DNB Markets as the source.

Recommendation structure and risk classification

DNB Markets recommendations are based on absolute performance:

- Buy - indicates an expected return greater than 10% within 12 months
- Hold - indicates an expected return between 0 and 10% within 12 months
- Sell - indicates an expected negative return within 12 months

The return-requirement bands above may be applied with some degree of flexibility depending on the liquidity and volatility characteristics of the individual share.

- High risk - Volatility over 40 percent.
- Medium risk - Volatility from 25 percent to 40 percent.
- Low risk - Volatility under 25 percent.

Current 6 months volatility rates this security as HIGH risk.

Investing in any security is subject to substantial risk. Return on investment may vary greatly.

Careful consideration for possible financial distress should be accounted for before investing in any security.

Price targets are based on a combination of several valuation methods such as discounted cash flow, pricing based on earnings multiples, multiple on book value, net asset value and peer comparison. Substantial material sources for coverage of this company include historical financial figures and communication with the company, and relevant third party information. Recommendations and historical target prices below may not compile all recommendations by DNB Markets, for further information please contact DNB Markets.

Price, Rating, and Price Target History Nordic Nanovector (NANO NO) as of 27-2-18



Conflict of interest

Readers should assume that DNB Markets may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services or other services to the company/companies

Share positions in the company:	Analyst*	Employees**	DNB***	Update
Number of shares	0	100	0	28/02/2018

*The analyst or any close associates. **Share positions include people involved in the production of credit and equity research, including people that could reasonably be expected to have access to it before distribution.

***Share positions as part of DNB Group. Holdings as part of DNB Markets investment services activity are not included.

Recommendation distribution and corporate clients for the last 12 months

	Buy	Hold	Sell	No rec	Total
Number	118	75	27	9	229
% of total	52 %	33 %	12 %	4 %	
DNB Markets client	23 %	14 %	3 %	2 %	95

Legal statement

These materials constitute research as defined in section 9-27 (1) of the Norwegian Securities Trading Regulations (Norwegian: verdipapirforskriften), and are not investment advice as defined in section 2-4(1) of the Norwegian securities trading act (Norwegian verdipapirhandelloven).

The analyst hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report, and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report. DNB Markets employees, including research analysts, may receive compensation that is generated by overall firm profitability. Confidentiality rules and internal rules restricting the exchange of information between different parts of DNB Markets/DNB Bank ASA or the DNB Group are in place to prevent employees of DNB Markets who are preparing this report from utilizing or being aware of information available in the DNB Group that may be relevant to the recipients' decisions. DNB Markets and the DNB Group have incorporated internal rules and regulations in order to avoid any potential conflicts of interest.

The Report has been prepared by DNB Markets, a division of DNB Bank ASA, a Norwegian bank organized under the laws of the Kingdom of Norway and under supervision by the Norwegian Financial Supervisory Authority, The Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK, and the Financial Supervisory Authority of Sweden. Details about the extent of our regulation by local authorities outside Norway are available from us on request.

It is issued subject to the General Business Terms for DNB Markets and information about the terms is available at www.dnb.no. For requests regarding the General Business Terms of the Singapore Branch of DNB Bank ASA, please contact +65 6212 6144. Information about the DNB Group can be found at www.dnb.com. DNB Markets is a member of The Norwegian Securities Dealers Association, which has issued recommendations and market standards for securities companies. The Association's Internet address where the recommendations and market standards can be found is: www.vpff.no. This report is not an offer to buy or sell any security or other financial instrument or to participate in any investment strategy. No liability whatsoever is accepted for any direct or indirect (including consequential) loss or expense arising from the use of this report. Distribution of research reports is in certain jurisdictions restricted by law. Persons in possession of this report should seek further guidance regarding such restrictions before distributing this report. Please contact DNB Markets at 08940 (+47 915 08940) for further information and inquiries regarding this report, including an overview on all recommendations from DNB Markets over the last 12 Months according to Market Abuse Regulations.

Additional information for clients in Singapore

The report has been distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should seek advice from a financial adviser regarding the suitability of any product referred to in the report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. You have received a copy of the report because you have been classified either as an accredited investor, an expert investor or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, in respect of certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 25, 27 and 36 of the FAA. Section 25 of the FAA requires a financial adviser to disclose material information concerning designated investment products which are recommended by the financial adviser to you as the client. Section 27 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 36 of the FAA requires a financial adviser to include, within any circular or written communications in which he makes recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6212 6144 in respect of any matters arising from, or in connection with, the report. The report is intended for and is to be circulated only to persons who are classified as an accredited investor, an expert investor or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6212 6144. We, the DNB group, our associates, officers and/or employees may have interests in any products referred to in the report by acting in various roles including as distributor, holder of principal positions, adviser or lender. We, the DNB group, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, we, the DNB group, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions which are not consistent with the information set out in the report.

In the United States

Each research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report; and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report.

The research analyst(s) named on this report are foreign research analysts as defined by FINRA Rule 1050. The only affiliate contributing to this research report is DNB Bank through its DNB Markets division ("DNB Markets/DNB Bank"); the foreign research analysts employed by DNB Markets/DNB Bank are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Markets/DNB Bank as a research provider or the subject company of a DNB Markets/DNB Bank research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc., a separately incorporated subsidiary of DNB Bank that is a U.S. broker-dealer and a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 200 Park Avenue, New York, NY 10166-0396, telephone number +1 212-551-9800.

In Canada

The Report has been distributed in reliance on the International Dealer Exemption pursuant to NI 31-103 subsection 8.18(2) and subsection 8.18(4)(b). Please be advised that: 1. DNB Bank ASA (DNB Markets) and DNB Markets, Inc. are not registered as a dealer in the local jurisdiction to make the trade. We provide our services in Canada as an exempt international dealer. 2. The jurisdiction of DNB Bank ASA (DNB Markets) and DNB Markets, Inc.'s head office is Norway. 3. There may be difficulty enforcing legal rights against DNB Bank ASA (DNB Markets) and DNB Markets, Inc. because all or substantially all of their assets may be situated outside of Canada. 4. The name and address of the agent for service of process for DNB Bank ASA (DNB Markets) and DNB Markets, Inc. in the local jurisdiction is:

Alberta: Blake, Cassels & Graydon LLP, 855 - 2nd Street S.W., Suite 3500, Bankers Hall East Tower, Calgary, AB T2P 4J8. British Columbia: Blakes Vancouver Services Inc., 595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC V7X 1L3. Manitoba: Aikins, MacAulay & Thorvaldson LLP, 30th Floor, Commodity Exchange Tower, 360 Main Street, Winnipeg, MB R3C 4G1. New Brunswick: Stewart McKelvey, Suite 1000, Brunswick House, 44 Chipman Hill, PO Box 7289, Station A, Saint John, NB E2L 2A9. Newfoundland and Labrador: Stewart McKelvey, Suite 1100, Cabot Place, 100 New Gower Street, P.O. Box 5038, St. John's, NL A1C 5V3. Nova Scotia: Stewart McKelvey, Purdy's Wharf Tower One, 1959 Upper Water Street, Suite 900, P.O. Box 997, Halifax, NS B3J 2X2. Northwest Territories: Gerald Stang, Suite 201, 5120-49 Street, Yellowknife, NT X1A 1P8. Nunavut: Field LLP, P.O. Box 1779, Building 1088C, Iqaluit, NU X0A 0H0. Ontario: Blakes Extra-Provincial Services Inc., Suite 4000, 199 Bay Street, Toronto, ON M5L 1A9. Prince Edward Island: Stewart McKelvey, 65 Grafton Street, Charlottetown, PE C1A 1K8. Québec: Services Blakes Québec Inc., 600 de Maisonneuve Boulevard Ouest, Suite 2200, Tour KPMG, Montréal, QC H3A 3J2. Saskatchewan: MacPherson, Leslie & Tyerman LLP, 1500 Continental Bank Building, 1874 Scarth Street, Regina, SK S4P 4E9. Yukon: Grant Macdonald, Macdonald & Company, Suite 200, Financial Plaza, 204 Lambert Street, Whitehorse, YK Y1A 3T2.

In Brazil

The analyst or any close associates do not hold nor do they have any direct/indirect involvement in the acquisition, sale, or intermediation of the securities discussed herein. Any financial interests, not disclosed above, that the analyst or any close associates holds in the issuer discussed in the report is limited to investment funds that do not mainly invest in the issuer or industry discussed in the report and the management of which these persons cannot influence.